Current and future biomarkers in colorectal cancer - PubMed (original) (raw)

Review

Current and future biomarkers in colorectal cancer

George Zarkavelis et al. Ann Gastroenterol. 2017.

Abstract

Colorectal cancer (CRC), one of the leading causes of death among cancer patients, is a heterogeneous disease and is characterized by diversions in multiple molecular pathways throughout its evolutionary process. To date, specific mutations in RAS and RAF genes are tested in everyday clinical practice along with mismatch repair gene deficiency, serving either as prognostic or predictive biomarkers, providing information for patient risk stratification and the choice of appropriate therapy. However, ongoing studies are focusing on the potential role of recently discovered genetic and epigenetic alterations in the management of CRC patients and their potential prognostic or predictive value. To overcome the problem of tumor heterogeneity as well as the practical obstacles of access to tumor tissue, and to achieve real-time monitoring of disease and therapy efficacy, liquid biopsies constitute a novel technology worth exploring. CRC screening and management is entering a new era where molecular testing will be applied to genomic material extracted from easily accessible bodily fluids.

Keywords: Colorectal cancer; biomarkers; liquid biopsies; prognostic and predictive markers.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None

Similar articles

• Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges.
  Koncina E, Haan S, Rauh S, Letellier E. Koncina E, et al. Cancers (Basel). 2020 Jan 30;12(2):319. doi: 10.3390/cancers12020319. Cancers (Basel). 2020. PMID: 32019056 Free PMC article. Review.
• Current and future biomarkers in the treatment of colorectal cancer.
  Cuyle PJ, Prenen H. Cuyle PJ, et al. Acta Clin Belg. 2017 Apr;72(2):103-115. doi: 10.1080/17843286.2016.1262996. Epub 2016 Dec 5. Acta Clin Belg. 2017. PMID: 27917697 Review.
• Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer.
  Sinicrope FA, Okamoto K, Kasi PM, Kawakami H. Sinicrope FA, et al. Clin Gastroenterol Hepatol. 2016 May;14(5):651-8. doi: 10.1016/j.cgh.2016.02.008. Epub 2016 Feb 9. Clin Gastroenterol Hepatol. 2016. PMID: 26872400 Free PMC article. Review.
• Genetic and epigenetic markers in colorectal cancer screening: recent advances.
  Singh MP, Rai S, Suyal S, Singh SK, Singh NK, Agarwal A, Srivastava S. Singh MP, et al. Expert Rev Mol Diagn. 2017 Jul;17(7):665-685. doi: 10.1080/14737159.2017.1337511. Epub 2017 Jun 19. Expert Rev Mol Diagn. 2017. PMID: 28562109 Review.
• Insulin-Like Growth Factor 2 (IGF2) Signaling in Colorectal Cancer-From Basic Research to Potential Clinical Applications.
  Kasprzak A, Adamek A. Kasprzak A, et al. Int J Mol Sci. 2019 Oct 3;20(19):4915. doi: 10.3390/ijms20194915. Int J Mol Sci. 2019. PMID: 31623387 Free PMC article. Review.

Cited by

• Atractylenolide I inhibited the development of malignant colorectal cancer cells and enhanced oxaliplatin sensitivity through the PDK1-FoxO1 axis.
  Sun Y, Liu Y, Cai Y, Han P, Hu S, Cao L. Sun Y, et al. J Gastrointest Oncol. 2022 Oct;13(5):2382-2392. doi: 10.21037/jgo-22-910. J Gastrointest Oncol. 2022. PMID: 36388699 Free PMC article.
• scPred: accurate supervised method for cell-type classification from single-cell RNA-seq data.
  Alquicira-Hernandez J, Sathe A, Ji HP, Nguyen Q, Powell JE. Alquicira-Hernandez J, et al. Genome Biol. 2019 Dec 12;20(1):264. doi: 10.1186/s13059-019-1862-5. Genome Biol. 2019. PMID: 31829268 Free PMC article.
• Dynamic Co-Evolution of Cancer Cells and Cancer-Associated Fibroblasts: Role in Right- and Left-Sided Colon Cancer Progression and Its Clinical Relevance.
  Ahmad Zawawi SS, Musa M. Ahmad Zawawi SS, et al. Biology (Basel). 2022 Jul 6;11(7):1014. doi: 10.3390/biology11071014. Biology (Basel). 2022. PMID: 36101394 Free PMC article. Review.
• Gastric tumorigenesis after radical resection combined with adjuvant chemotherapy for colorectal cancer: two case reports and a literature review.
  Li T, Liu G, Li J, Cui J, Wang X, Li W, Zhao Z, Zhang K, Liu T. Li T, et al. J Int Med Res. 2021 Apr;49(4):3000605211007050. doi: 10.1177/03000605211007050. J Int Med Res. 2021. PMID: 33858250 Free PMC article.
• Screening Gene Expression-Related Alternative Splicing Event Signature for Colon Cancer Prognostic Prediction.
  Xu J, Chen J, Cheng C, Li H, Gao P, Zheng J, Wang J. Xu J, et al. J Oncol. 2022 Jan 27;2022:9952438. doi: 10.1155/2022/9952438. eCollection 2022. J Oncol. 2022. PMID: 35126520 Free PMC article.

References

1. 1. Kolligs FT. Diagnostics and Epidemiology of Colorectal Cancer. Visc Med. 2016;32:158–164. - PMC - PubMed
2. 1. Coppedè F, Lopomo A, Spisni R, Migliore L. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J Gastroenterol. 2014;20:943–956. - PMC - PubMed
3. 1. Weiss JM, Pfau PR, O'Connor ES, et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results—Medicare data. J Clin Oncol. 2011;29:4401–4409. - PMC - PubMed
4. 1. Missiaglia E, Jacobs B, D'Ario G, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014;25:1995–2001. - PubMed
5. 1. Kaz AM, Wong CJ, Dzieciatkowski S, Luo Y, Schoen RE, Grady WM. Patterns of DNA methylation in the normal colon vary by anatomical location, gender, and age. Epigenetics. 2014;9:492–502. - PMC - PubMed

Publication types

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • scite Smart Citations

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal